logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Sarepta Pharmaceuticals Jumps on Competitor’s Failure

  +Follow August 16, 2013 9:54AM
Share:
Tickers Mentioned:

Sarepta Therapeutics Inc. (SRPT) experienced a bit of schadenfreude on Aug. 16 as a direct competitor stumbled badly at the finish line.

Competitor GlaxoSmithKline plc (GSK) had been neck-and-neck with Serepta in the race to develop a breakthrough muscle disorder drug to treat Duchenne Muscular Dystrophy. Both drugs were far ahead of the pack in the development process.

That is, until Baird analyst Brian Skorney reported that Glaxo’s drug, drisapersen, has encountered major stumbling blocks on several fronts that could significantly hamper development. Skorney cited clinical, regulatory, and commercials issues with the drug. Most importantly, the drug did not seem to effectively treat symptoms of the disease at the targeted dose.

Serepta’s drug, eteplirsen, so far has seemed to be effective at treating symptoms of Duchenne. Clinical trials have taken place in the UK. On Aug. 7 the company released promising clinical trial information, which will form the basis of their application for US FDA approval in early 2014.

Duchenne is a severely debilitating form of muscular dystrophy. The recessive muscular degenerative disorder affects approximately 1 in 3,600 boys, and life expectancy for sufferers is usually around 25. A drug from either company would be the first on the American market designed to treat the disorder.

The London-based GlaxoSmithKline , which is the fourth largest pharmaceutical company in the world, shrugged off the setback. Their stock is up .33 percent to hit $51.70 a share.

Serepta is up 6.77 percent to hit $34.21 a share.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for GSK
lord of trading
20 Oct 14 10:51:51
$GSK Up A Half A Percent http://t.co/VxTwTqihSB
Becky Hiu
20 Oct 14 10:34:09
"@Ro_Patel: Reuters: EU offers benefits of "orphan" disease status to Ebola drugs - http://t.co/6nV3QBXm54 - $TKMR $GSK $SRPT $JNJ $NLNK"
Ro Patel
20 Oct 14 10:33:09
Reuters: EU offers benefits of "orphan" disease status to Ebola drugs - http://t.co/mo8LYi2lTw - $TKMR $TKM.CA $GSK $SRPT $JNJ $NLNK
Rajkumar Gupta
20 Oct 14 10:08:03
RT @FiercePharma: GSK private eyes' son allowed first visit to parents in China jail as trial nears http://t.co/nV91TrrZ33 $GSK #pharma by …
NASDAQ
20 Oct 14 10:07:04
$GSK - Report of Foreign Issuer (6-k) http://t.co/HKWUGPDm0j
StockNews
20 Oct 14 10:07:03
$GSK - Report of Foreign Issuer (6-k) http://t.co/YhThOUhZxT
NASDAQ
20 Oct 14 10:04:12
$GSK - Report of Foreign Issuer (6-k) http://t.co/CA0lBoKVmT
StockNews
20 Oct 14 10:04:11
$GSK - Report of Foreign Issuer (6-k) http://t.co/Dzn68ewv3C
Hemery Corp.
20 Oct 14 10:04:03
Anyone confirms this story? $NLNK $GSK $APT $IBIO $LAKE http://t.co/rk3iYI0721
NASDAQ
20 Oct 14 10:01:34
$GSK - Report of Foreign Issuer (6-k) http://t.co/R8cwbINr14
StockNews
20 Oct 14 10:01:12
$GSK - Report of Foreign Issuer (6-k) http://t.co/KRk6wuBOFI
NASDAQ
20 Oct 14 09:55:06
$GSK - Report of Foreign Issuer (6-k) http://t.co/wYQl6lpIXt
StockNews
20 Oct 14 09:55:05
$GSK - Report of Foreign Issuer (6-k) http://t.co/KcqxFH0Zer
Ananya
20 Oct 14 09:31:40
RT @ZacksResearch: These healthcare stocks are in focus amid Ebola fears. $BCRX $AGN $GSK $INO $TKMR $SRPT $NLNK http://t.co/kOJEzReT5U
WKRB News
20 Oct 14 09:19:44
GlaxoSmithKline plc’s “Hold” Rating Reaffirmed at Baader Helvea $GSK http://t.co/FdG2mIv2fe
Stockaholics
20 Oct 14 09:05:03
After Massive Gains On Penny Stock Picks, another New Pick Is Coming! Check it out: http://t.co/YX0NLZhRQ5 $LFAP $GSK $ROX
Donna Young
20 Oct 14 08:59:36
ICYMI: US Capitol Capsule: Ebola disagreements emerge among US officials http://t.co/CgYgrfUM6M #Ebola #NIH #NIAID $GSK $NLNK $JNJ #CDC
Yu Zhu
20 Oct 14 08:59:07
RT @ScripDonnaDC: .@emoryhealthcare launches #Ebola protocols website http://t.co/AxcqruGyTF #CDC #WHO #NIH #ZMapp $CMRX $BCRX $TKMR $GSK $…
Donna Young
20 Oct 14 08:59:00
ICYMI:CDC upgrades Ebola guidelines http://t.co/lq6CPlpQ2s #CDC #Ebola #WHO #pharma #NIH $CMRX $BCRX $TKMR $GSK $NLKL $JNJ $SRPT
SCRIP Intelligence
20 Oct 14 08:53:52
RT @ScripDonnaDC: .@emoryhealthcare launches #Ebola protocols website http://t.co/AxcqruGyTF #CDC #WHO #NIH #ZMapp $CMRX $BCRX $TKMR $GSK $…
Sandy Middlemas
20 Oct 14 08:52:50
Analysts expecting Q3 EPS at $GSK will come in at 24p down from 28p the previous year. Announcement 22nd October. Long term HOLDing.
Stock Moo
20 Oct 14 08:52:49
$gsk: Director/PDMR Shareholding http://t.co/nrdMUxVfbg
Mike Isaacson
20 Oct 14 08:44:37
RT @pharmalot: Pharmalot.. Pharmalittle.. Good Morning.. welcome to the working week.. http://t.co/pk02d2QNVT #pharma #ebola $ABBV $SHPG $R…
V.S. Schulz
20 Oct 14 08:42:15
RT @ScripDonnaDC: .@emoryhealthcare launches #Ebola protocols website http://t.co/AxcqruGyTF #CDC #WHO #NIH #ZMapp $CMRX $BCRX $TKMR $GSK $…
Donna Young
20 Oct 14 08:40:58
.@emoryhealthcare launches #Ebola protocols website http://t.co/AxcqruGyTF #CDC #WHO #NIH #ZMapp $CMRX $BCRX $TKMR $GSK $NLNK $JNJ $SRPT
efinancialpub.com
20 Oct 14 08:38:53
RT @ZacksResearch: These healthcare stocks are in focus amid Ebola fears. $BCRX $AGN $GSK $INO $TKMR $SRPT $NLNK http://t.co/kOJEzReT5U
Zacks.com
20 Oct 14 08:38:00
These healthcare stocks are in focus amid Ebola fears. $BCRX $AGN $GSK $INO $TKMR $SRPT $NLNK http://t.co/kOJEzReT5U
p_code
20 Oct 14 08:19:34
$IBIO on the fly $NLNK $VSR $LAKE $APT $INO $VSR $TKMR $GSK http://t.co/6qTxih60HE
janet gale
20 Oct 14 08:14:07
$GSK - GlaxoSmithKline PLC Director/PDMR Shareholding http://t.co/hH1Yzm1HLj
janet gale
20 Oct 14 08:09:07
$GSK - GlaxoSmithKline PLC Director/PDMR Shareholding http://t.co/McC1UsjQdx
janet gale
20 Oct 14 08:05:08
$GSK - GlaxoSmithKline PLC Director/PDMR Shareholding http://t.co/hq1CIsPloO
janet gale
20 Oct 14 08:00:11
$GSK - GlaxoSmithKline PLC Director/PDMR Shareholding http://t.co/3Dkoo6P1kt
ValueWalk
20 Oct 14 07:19:18
Dodge & Cox’ Stock Fund Third Quarter 2014 Commentary http://t.co/lQoCX2to4z $GSK $S $SLB $BHI $TEL $GLW http://t.co/1sC1chckeK
Stock Moo
20 Oct 14 06:52:51
$gsk: ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S. http://t.co/SFsJHdwqNi
p_code
20 Oct 14 06:39:58
New CDC #Ebola guidelines for hospital protective gear 10/20/2014: http://t.co/c9nWmLaK0o $APT $VSR $LAKE $NLNK $IBIO $TKMR $GSK
Amila Karunaratne
20 Oct 14 06:39:03
#ambervinsonRN Who paid you to travel ??? Which of these companies $jnj $gsk $nlnk so you could possibly spread ??? #Ebola @A_Karunaratne
On Time Picks
20 Oct 14 06:32:53
RNsidersbuying: $GSK $43.35 - By late 1998, Dr. Sullivan: RNsidersbuying http://t.co/HrI8u4Odpx
Jonathan Rockoff
20 Oct 14 06:29:17
@TomBurtonWSJ on the race to develop an Ebola vaccine and a @NIAIDNews cell biologist behind it: http://t.co/30owlsiGRm $GSK
Sahil Alvi
20 Oct 14 06:25:46
$GSK's price does not reflect its promising Ebola vaccine whose development is being accelerated. Anywhere from 25 to 40% upside from here.
4-traders.com
20 Oct 14 06:25:03
GlaxoSmithKline : Earnings Releases, Conference Call Schedule, Acquisitions, Drug Launches, and Initiation ... http://t.co/c7CemvJV4x $GSK
Elinvitado
20 Oct 14 06:19:18
RT @pharmalot: Pharmalot.. Pharmalittle.. Good Morning.. welcome to the working week.. http://t.co/pk02d2QNVT #pharma #ebola $ABBV $SHPG $R…
Alastair Neil Lamber
20 Oct 14 06:18:09
RT @pharmalot: Pharmalot.. Pharmalittle.. Good Morning.. welcome to the working week.. http://t.co/pk02d2QNVT #pharma #ebola $ABBV $SHPG $R…
janet gale
20 Oct 14 06:07:15
$GSK - GlaxoSmithKline plc 3Q 2014 -- Forecast http://t.co/QWfLCKnhPP
NASDAQ
20 Oct 14 06:07:08
$GSK - GlaxoSmithKline plc 3Q 2014 -- Forecast http://t.co/itG9xlG5lo
StockNews
20 Oct 14 06:07:07
$GSK - GlaxoSmithKline plc 3Q 2014 -- Forecast http://t.co/cNdt3a1xin
WSJ Health News
20 Oct 14 06:05:10
RT @pharmalot: Pharmalot.. Pharmalittle.. Good Morning.. welcome to the working week.. http://t.co/pk02d2QNVT #pharma #ebola $ABBV $SHPG $R…
Stefanie Ilgenfritz
20 Oct 14 06:05:10
RT @pharmalot: Pharmalot.. Pharmalittle.. Good Morning.. welcome to the working week.. http://t.co/pk02d2QNVT #pharma #ebola $ABBV $SHPG $R…
Purdue Selfies
20 Oct 14 06:03:33
RT @pharmalot: Pharmalot.. Pharmalittle.. Good Morning.. welcome to the working week.. http://t.co/pk02d2QNVT #pharma #ebola $ABBV $SHPG $R…
janet gale
20 Oct 14 06:03:13
$GSK - ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S. http://t.co/kTVdSuXudq
StockNews
20 Oct 14 06:03:00
$GSK - ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S. http://t.co/LeluKTfdbw
				
				
  +Follow August 16, 2013 9:54AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.